Quviviq (Daridorexant) for Seniors: What to Know
Medically reviewed by Veronica Hackethal | MD, MSc, Harvard University | University of Oxford | Columbia Vagelos College of Physicians and Surgeons on July 25th, 2026.
Published on July 21st, 2026. Updated on July 25th, 2026.
Key takeaways
Daridorexant blocks orexin signaling rather than broadly sedating the brain, making it structurally different from benzodiazepines and Z-drugs that carry serious risks in older adults.
Clinical trials for Quviviq included adults over 65, giving it more age-relevant evidence than many legacy sleep medications.
Fall risk and morning sedation are still real concerns for seniors taking daridorexant, and each patient needs an individualized evaluation before starting treatment.
Polypharmacy is a key complication to assess, because daridorexant is metabolized through the CYP3A4 pathway and interacts with many drugs commonly prescribed to older adults.
Cognitive behavioral therapy for insomnia (CBT-I) remains the evidence-based first-line approach and should always be discussed before any sleep medication is considered.
What Daridorexant Is and How It Works Differently
Daridorexant, sold under the brand name Quviviq, is a dual orexin receptor antagonist approved by the FDA in 2022 for adults with insomnia disorder. Unlike older sleep medications that broadly suppress the central nervous system, daridorexant works by blocking orexin, a brain chemical that actively promotes wakefulness. When orexin signaling is reduced, the brain can transition more naturally into sleep without the heavy sedative effect that older drug classes produce.
This distinction matters enormously for older adults. Traditional sedative-hypnotics, including benzodiazepines and so-called Z-drugs like zolpidem, work through mechanisms that are associated with significant risks in aging populations. Daridorexant's more targeted approach represents a genuine departure from that older pharmacology, though it is not entirely without risk.
Why Sleep Problems Are So Common After 65
Sleep changes with age in several important ways. Older adults tend to experience shifts in their circadian rhythm, reduced time spent in deep restorative sleep stages, and earlier sleep-wake cycles. These changes are biological and not simply a matter of lifestyle.
Chronic insomnia affects roughly 50% of adults over 65, making it one of the most frequently reported complaints in geriatric medicine. The consequences go well beyond feeling tired. Poor sleep in seniors is associated with increased fall risk, accelerated cognitive decline, cardiovascular events, and higher rates of depression. Finding a treatment approach that works safely in this age group is not just a matter of comfort. It can have meaningful effects on long-term health outcomes.
Cognitive behavioral therapy for insomnia, known as CBT-I, remains the first-line recommended treatment before any medication is considered. CBT-I addresses the thoughts and behaviors that perpetuate insomnia without introducing any pharmacologic risk. For seniors who have not responded adequately to CBT-I, or who need additional support, medication options become relevant.
The Case for Daridorexant in Older Adults
One practical advantage of daridorexant is that its clinical trials specifically included adults over 65. The drug demonstrated efficacy in reducing the time it takes to fall asleep and reducing wake time after sleep onset in this age group. That age-relevant evidence base is more robust than what exists for many legacy sleep medications, which were often studied primarily in younger adult populations.
Importantly, daridorexant is not listed on the American Geriatrics Society Beers Criteria, a widely used reference that identifies medications considered potentially inappropriate for older adults. It also does not appear to carry the rebound insomnia or physical dependence risks associated with benzodiazepines and Z-drugs. These characteristics make it a more attractive pharmacologic option for many seniors, though a physician should always assess individual suitability.
Safety Considerations Specific to Seniors
No sleep medication is without risk in older adults, and daridorexant is no exception. The most commonly reported side effects include somnolence, headache, and dizziness. In a population already at elevated fall risk, even mild dizziness or morning grogginess can have serious consequences.
Morning-after sedation is a particular concern for seniors who wake early or who have pre-existing balance or gait issues. Patients should be advised not to take the medication unless they have at least 7 hours available for sleep. Sleep-related behaviors such as sleepwalking or, in rare cases, sleep-driving are a documented risk across the class of sleep medications and are not exclusive to older sedatives.
Daridorexant has not been studied in patients with severe hepatic impairment, which is a relevant gap given that liver function naturally changes with age. Prescribers should factor this into their evaluation for individual patients.
Comparing Common Insomnia Treatments for Older Adults
Choosing the right treatment requires understanding how the available options stack up against each other across several dimensions that matter most for seniors.
Medication |
Mechanism |
Beers Criteria Listed |
Fall Risk |
Dependence Potential |
Efficacy for Sleep Onset |
|---|---|---|---|---|---|
Daridorexant (Quviviq) |
Orexin receptor antagonist |
No |
Moderate (dizziness, sedation) |
Low |
Moderate to good |
Zolpidem (Ambien) |
GABA-A receptor modulator |
Yes |
High |
Moderate |
Good |
Ramelteon (Rozerem) |
Melatonin receptor agonist |
No |
Low |
Very low |
Modest |
Low-dose Doxepin (Silenor) |
Histamine receptor antagonist |
No (at low doses) |
Low to moderate |
Low |
Modest |
Benzodiazepines and Z-drugs like zolpidem and eszopiclone carry well-documented risks in older adults, including falls, memory impairment, and the potential for dependence. Ramelteon and low-dose doxepin are frequently recommended alternatives, though their efficacy tends to be more modest. Daridorexant sits in a favorable position relative to older drug classes, but it is not a one-size-fits-all solution.
Practical Dosing and Prescribing Guidance
The recommended doses for daridorexant are 25 mg or 50 mg, taken within 30 minutes of bedtime. No dose reduction is required solely on the basis of age, which simplifies prescribing compared to some other medications. However, seniors taking CYP3A4 inhibitors, a category that includes several drugs commonly prescribed for heart conditions, antifungal infections, and other chronic conditions, may require the lower dose because daridorexant is metabolized through that enzyme pathway.
Polypharmacy is one of the most important factors to assess before initiating treatment in older adults. A thorough medication review can identify potential interactions before they become a clinical problem. Prescribers should also evaluate fall risk, cognitive status, and liver function as part of the baseline assessment.
Doctronic, which has completed over 22 million AI consultations and maintains a 99.2% treatment plan alignment with board-certified physicians, offers a practical starting point for seniors and families who want to understand their options before a clinical appointment. Raising these questions early, whether through a 24/7 AI consultation or a $39 video visit with a physician, can make the prescribing conversation more informed and productive.
Frequently Asked Questions
Daridorexant has a more favorable safety profile than older sedative-hypnotics for seniors. It is not listed on the Beers Criteria as a medication to avoid in older adults. However, risks like dizziness, morning sedation, and drug interactions still apply, so a clinician should evaluate each individual before prescribing Quviviq.
Yes, dizziness and somnolence are among the most common side effects of daridorexant, and these carry a heightened fall risk for older adults. Morning-after sedation is a particular concern for seniors who wake early or already have impaired balance. Discussing fall history with a clinician before starting this medication is strongly recommended.
Zolpidem is listed on the Beers Criteria and is associated with falls, memory impairment, and dependence in older adults. Daridorexant is not on the Beers Criteria and does not carry the same dependence risk. While daridorexant appears to be a safer option for many seniors, individual risk factors still need to be evaluated by a clinician.
Polypharmacy is a significant consideration. Daridorexant is metabolized by the CYP3A4 enzyme pathway, so seniors taking CYP3A4 inhibitors, which are common in older adults, may need dose adjustments. A thorough medication review by a prescriber is essential before starting Quviviq to avoid harmful interactions.
The standard doses are 25 mg or 50 mg, taken within 30 minutes of bedtime. No dose adjustment is required solely because of age. However, seniors on certain interacting medications may need the lower dose. Patients should ensure they have at least 7 hours available for sleep before taking daridorexant to reduce next-day drowsiness.
The Bottom Line
Daridorexant represents a meaningful step forward in insomnia treatment for older adults, offering a more targeted mechanism and a more favorable risk profile than older sedative-hypnotics. That said, age-related factors like fall risk, polypharmacy, and liver function still require careful evaluation before starting any sleep medication. CBT-I should always be considered first. Doctronic, the first AI legally authorized to practice medicine, offers 24/7 consultations and $39 video visits so seniors and their families can start that conversation anytime. With over 22 million AI consultations completed, Doctronic can help you explore your options with confidence. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get sleep health advice
Chat Now